Evidence of microvascular dysfunction in heart failure with preserved ejection fraction

Heart

Volumn 102, Issue 4, 2016, Pages 278-284

  Lee, Joshua F ^a   Barrett O'Keefe, Zachary ^a,b   Garten, Ryan S ^a   Nelson, Ashley D ^a   Ryan, John J ^c   Nativi, Jose N ^c   Richardson, Russell S ^a,b   Wray, D Walter ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NITRIC ACID DERIVATIVE;

AGE; AGED; AREA UNDER THE CURVE; ARTERY BLOOD FLOW; ARTERY CONDUIT; ARTERY DIAMETER; ARTICLE; BLOOD FLOW VELOCITY; BRACHIAL ARTERY DIAMETER; BRACHIAL ARTERY DILATION; BRACHIAL ARTERY FLOW; CARDIAC CONDUIT; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FLOW MEDIATED DILATION; GENDER; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; HUMAN; HYPEREMIA; MEAN ARTERIAL PRESSURE; MICROVASCULAR DYSFUNCTION; MICROVASCULAR FUNCTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SHEAR RATE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; VASCULARIZATION; BLOOD FLOW; BRACHIAL ARTERY; CASE CONTROL STUDY; DOPPLER ULTRASONOGRAPHY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MALE; MICROCIRCULATION; VASODILATATION; WALK TEST;

AGED; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; CASE-CONTROL STUDIES; FEMALE; HEART FAILURE; HUMANS; HYPEREMIA; MALE; MICROCIRCULATION; REGIONAL BLOOD FLOW; STROKE VOLUME; ULTRASONOGRAPHY, DOPPLER; VASODILATION; VENTRICULAR FUNCTION, LEFT; WALK TEST;

EID: 84959322987     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2015-308403     Document Type: Article

References (30)

1. Bhatia R, Tu J, Lee D, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-9.
2. Bursi F, Weston S, Redfield M, et al. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209-16.
3. Owan T, Hodge D, Herges R, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-9.
4. Fischer D, Rossa S, Landmesser U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J 2005; 26: 65-9.
5. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol 1992; 19: 918-25.
6. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991; 84: 1589-96.
7. Witman MAH, Fjeldstad AS, McDaniel J, et al. Vascular function and the role of oxidative stress in heart failure, heart transplant, and beyond. Hypertension 2012; 60: 659-68.
8. Hundley WG, Bayram E, Hamilton CA, et al. Leg flow-mediated arterial dilation in elderly patients with heart failure and normal left ventricular ejection fraction. Am J Physiol Heart Circ Physiol 2007; 292: H1427-34.
9. Haykowsky MJ, Herrington DM, Brubaker PH, et al. Relationship of flow-mediated arterial dilation and exercise capacity in older patients with heart failure and preserved ejection fraction. J Gerontol A Biol Sci Med Sci 2013; 68: 161-7.
10. Farrero M, Blanco I, Batlle M, et al. Pulmonary hypertension is related to peripheral endothelial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail 2014; 7: 791-8.
11. Pyke KE, Tschakovsky ME. The relationship between shear stress and flow-mediated dilatation: Implications for the assessment of endothelial function. J Physiol 2005; 568: 357-69.
12. Harris RA, Nishiyama SK, Wray DW, et al. Ultrasound assessment of flow-mediated dilation. Hypertension 2010; 55: 1075-85.
13. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 2010; 56: 845-54.
14. Matsue Y, Suzuki M, Nagahori W, et al. Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 2013; 168: 36-40.
15. Akiyama E, Sugiyama S, Matsuzawa Y, et al. Incremental prognostic significance of peripheral endothelial dysfunction in patients with heart failure with normal left ventricular ejection fraction. J Am Coll Cardiol 2012; 60: 1778-86.
16. Logason K, Barlin T, Jonsson ML, et al. The importance of Doppler angle of insonation on differentiation between 50-69% and 70-99% carotid artery stenosis. Eur J Vasc Endovasc Surg 2001; 21: 311-13.
17. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2014; 11: 507-15.
18. Wachter R, Edelmann F. Diagnosis of heart failure with preserved ejection fraction. Heart Fail Clin 2014; 10: 399-406.
19. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 2144-50.
20. Borlaug BA. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J 2014; 78: 20-32.
21. Dhakal BP, Malhotra R, Murphy RM, et al. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: The role of abnormal peripheral oxygen extraction. Circ Heart Fail 2015; 8: 286-94.
22. Melkumyants AM, Balashov SA, Khayutin VM. Endothelium dependent control of arterial diameter by blood viscosity. Cardiovasc Res 1989; 23: 741-7.
23. de Berrazueta JR, Guerra-Ruiz A, Garcia-Unzueta MT, et al. Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. Eur J Heart Fail 2010; 12: 477-83.
24. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-71.
25. Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
26. Varin R, Mulder P, Tamion F, et al. Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : Role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 2000; 102: 351-6.
27. Tousoulis D, Oikonomou E, Siasos G, et al. Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure. Atherosclerosis 2013; 227: 367-72.
28. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362: 777-81.
29. Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-67.
30. Fu M, Zhou J, Sun A, et al. Efficacy of ACE inhibitors in chronic heart failure with preserved ejection fraction-A meta analysis of 7 prospective clinical studies. Int J Cardiol 2012; 155: 33-8.